To assess the role of IVUS in
Condition or disease | Intervention/treatment |
---|---|
Iliocaval Compression Syndrome | Device: intravascular ultrasound |
Study Type : | Observational |
Estimated Enrollment : | 70 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Role of Intravascular Ultrasound(IVUS) in Management of Acute and Chronic Iliocaval Obstruction |
Estimated Study Start Date : | May 2020 |
Estimated Primary Completion Date : | August 30, 2021 |
Estimated Study Completion Date : | March 30, 2022 |
Tracking Information | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date | July 16, 2019 | |||||||||
First Posted Date | July 18, 2019 | |||||||||
Last Update Posted Date | May 11, 2020 | |||||||||
Estimated Study Start Date | May 2020 | |||||||||
Estimated Primary Completion Date | August 30, 2021 (Final data collection date for primary outcome measure) | |||||||||
Current Primary Outcome Measures |
|
|||||||||
Original Primary Outcome Measures |
|
|||||||||
Change History | ||||||||||
Current Secondary Outcome Measures |
|
|||||||||
Original Secondary Outcome Measures | Same as current | |||||||||
Current Other Pre-specified Outcome Measures | Not Provided | |||||||||
Original Other Pre-specified Outcome Measures | Not Provided | |||||||||
Descriptive Information | ||||||||||
Brief Title | Role of IVUS in Management of Iliocaval Obstruction | |||||||||
Official Title | Role of Intravascular Ultrasound(IVUS) in Management of Acute and Chronic Iliocaval Obstruction | |||||||||
Brief Summary |
To assess the role of IVUS in
|
|||||||||
Detailed Description |
Acute and chronic venous disorders of the lower extremities affect millions of people and cause substantial disability. Surgeons and pathologists identified the presence of 'spur-like' abnormalities of the left common iliac vein, these abnormalities were hypothesized to result from compression and/or irritation from the adjacent crossing right common iliac artery. In the 1990s, physicians, starting to perform catheter-directed thrombolysis to treat extensive deep vein thrombosis (DVT), observed that about 50% of patients had an iliac vein stenosis.Treatment is aimed at ameliorating the symptoms and, whenever possible, at correcting the underlying abnormality. Graduated compression is the cornerstone of modern therapy. Deep system disease is often refractory to treatment, but superficial system disease can usually be treated by ablating the refluxing vessels. Effective venous return from the lower extremities requires the interaction of the heart, a pressure gradient, the peripheral muscle pumps of the leg, and competent venous valves. In the absence of pathology, this system functions to reduce venous pressure from approximately 100 mm Hg to a mean of 22 mm Hg within a few steps. Nonthrombotic venous compression patients with left common iliac vein compression can present in the 2nd or 3rd decade of life and are more common in women. Patients can have limb pain, limb swelling, ipsilateral chronic venous insufficiency, lipodermatosclerosis, recurrent superficial venous thrombophlebitis, and venous claudication. Thrombotic iliofemoral venous compression with a predisposing anatomic configuration with a prothrombotic physiological state can present with acute pain and swelling of the left lower extremity consistent with an acute iliofemoral DVT mostly phlegmasia cerulea dolens . In the acute phase, patients with a patent foramen ovale can also present with a pulmonary embolism, cryptogenic stroke, with or without pulmonary embolism, or systemic arterial embolism. The abnormalities in venous physiology associated with chronic venous disease, and their quantification by diagnostic tests, are also considerably more complex than for PAD. With CVD one must gauge the effects of obstruction and/or reflux in a vascular bed uniquely designed to return venous blood to the heart against gravity with the aid of a peripheral muscle pump and in phase with respiratory mechanics. Duplex ultrasound (DUS) is initial diagnostic test. The criteria include: poststenotic turbulence, as indicated by a mosaic velocity profile, abnormal Doppler signal at the area of stenosis, continuous flow with the Valsalva maneuver, and sluggish with no spontaneous flow and poor augmentation and no respiratory phasicity. But there is limitations as obesity ,casts, dressings, open wounds, Patients with severe edema/swelling and limited patient mobility. Cross-sectional imaging includes computed tomographic venography (CTV) with venous phase contrast or magnetic resonance venography (MRV). Catheter-based phlebography traditionally is considered to be the most definitive technique for the evaluation of venous obstruction, supplemented with direct pressure measurements across an area of perceived stenosis in order to determine whether a pressure gradient exists. Intravascular ultrasound (IVUS) uses a catheter-based ultrasound probe that enables high-resolution evaluation of the vein wall and internal venous architecture in 360. IVUS is more sensitive than phlebography for the detection and characterization of iliac vein pathology. This would be expected since IVUS gives a 360 image versus a single plane image shown by standard phlebograms. Intravascular ultrasound also identifies intraluminal trabeculations, septations, webs, and wall thickening, which can be minimized or missed on standard phlebography, plus reduced radiation exposure in contrast to other modalities. IVUS is better in evaluating lesion morphology, accurate assessment of luminal dimensions, transmural lesion characteristics. Delineation by IVUS of the spatial distribution of the lesion in a concentric or eccentric pattern and the presence of a soft (fibrous) or hard (calcified) plaque may influence the choice of endovascular therapy as well as predict the risk of immediate or late complications (ie, perforation, thrombosis, restenosis). Evaluation of lesion volume before and after the procedure by IVUS provides a quantitative method to estimate the amount of lesion debulking or displacement and a reference point from which to assess the lesion recurrence/restenosis. IVUS also fulfills many of the necessary requirements of a guidance system for endovascular procedures, namely precise delivery and positioning of stents within target lesions. IVUS is particularly helpful in assessing the relationship of the ostia of branch vessels to the lesion that can be used as landmarks during procedures. |
|||||||||
Study Type | Observational | |||||||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
|||||||||
Target Follow-Up Duration | Not Provided | |||||||||
Biospecimen | Not Provided | |||||||||
Sampling Method | Non-Probability Sample | |||||||||
Study Population | subjects with with acute or chronic iliocaval obstruction CEAP classification 3-6. | |||||||||
Condition | Iliocaval Compression Syndrome | |||||||||
Intervention | Device: intravascular ultrasound
IVUS creates axial images perpendicular to the long axis of the catheter by transmitting sound waves covering 360 degrees around the tip of the catheter, which is delivered into the lumen of the vessel over a guidewire.
|
|||||||||
Study Groups/Cohorts | Not Provided | |||||||||
Publications * |
|
|||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||||||||
Recruitment Information | ||||||||||
Recruitment Status | Recruiting | |||||||||
Estimated Enrollment |
70 | |||||||||
Original Estimated Enrollment |
73 | |||||||||
Estimated Study Completion Date | March 30, 2022 | |||||||||
Estimated Primary Completion Date | August 30, 2021 (Final data collection date for primary outcome measure) | |||||||||
Eligibility Criteria |
Inclusion Criteria:
Exclusion Criteria: 1 - concomitant peripheral arterial disease in the affected limb. 2-life expectancy less than 5 years. 3- pregnancy 4- malignancy 5-raised renal chemistry 6-pelvic fibrosis 7- contraindication to anti-coagulation therapy. 8-congenital venous malformations 9-Not providing informed consent 10-Any concurrent disease as heart failure |
|||||||||
Sex/Gender |
|
|||||||||
Ages | 18 Years to 60 Years (Adult) | |||||||||
Accepts Healthy Volunteers | Not Provided | |||||||||
Contacts |
|
|||||||||
Listed Location Countries | Egypt | |||||||||
Removed Location Countries | ||||||||||
Administrative Information | ||||||||||
NCT Number | NCT04024215 | |||||||||
Other Study ID Numbers | IVUS in iliocaval obstruction | |||||||||
Has Data Monitoring Committee | Not Provided | |||||||||
U.S. FDA-regulated Product |
|
|||||||||
IPD Sharing Statement |
|
|||||||||
Responsible Party | Sahar Hamdi Ali Abdel-kader, Assiut University | |||||||||
Study Sponsor | Assiut University | |||||||||
Collaborators | Not Provided | |||||||||
Investigators |
|
|||||||||
PRS Account | Assiut University | |||||||||
Verification Date | May 2020 |